Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Pediatr Blood Cancer. 2022 Oct;69(10):e29882. doi: 10.1002/pbc.29882. Epub 2022 Jul 16.

Abstract

The European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS-05 (EUDRACT 2005-001139-31) and in MTS-2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0-18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow-up of 50 months (range, 6-176) for living patients, nine patients remain alive off therapy and two died. Five-year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5-93.9) and 74.1% (95% CI: 28.1-93.0).

Keywords: children; hemangioendothelioma; soft tissue sarcoma; surgery.

MeSH terms

  • Adolescent
  • Child
  • Clinical Studies as Topic
  • Hemangioendothelioma, Epithelioid* / therapy
  • Humans
  • Sarcoma* / pathology
  • Sarcoma* / therapy
  • Soft Tissue Neoplasms* / pathology
  • Soft Tissue Neoplasms* / therapy

Associated data

  • ClinicalTrials.gov/NCT00379457
  • EudraCT/2005-001139-31